Actively Recruiting

Phase 3
Age: 4Years +
All Genders
NCT07082725

A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease (NPC)

Led by Azafaros A.G. · Updated on 2026-05-05

72

Participants Needed

34

Research Sites

122 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

An 18-month double-blind, randomized, placebo-controlled, multicenter, Phase 3 study to evaluate the safety and efficacy of oral nizubaglustat (AZ-3102) in late-infantile and juvenile forms of Niemann-Pick type C disease

CONDITIONS

Official Title

A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease (NPC)

Who Can Participate

Age: 4Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Signed informed consent
  • Confirmed diagnosis of Niemann-Pick type C disease
  • Unable or unwilling to take miglustat, or unsatisfactorily treated with miglustat
  • Male and female participants aged 4 years and older at consent
  • Onset of neurological symptoms between 2 and 15 years of age
  • Disability level at baseline with ataxic disturbances and total SARA score between 3 and 30
  • Sexually active females of childbearing potential willing to follow contraceptive guidance
  • Male participants with female partners of childbearing potential willing to follow contraceptive guidance
Not Eligible

You will not qualify if you...

  • Medical conditions other than Niemann-Pick type C disease that could affect study results
  • Body weight less than 10 kg
  • Presence of another neurologic disease
  • Moderate or severe liver impairment
  • Moderate or severe kidney impairment
  • Platelet count below 100 x 10^9/L
  • Recent changes in anti-epileptic treatment dose within 3 months or new treatment within 1 month before baseline
  • Use of investigational drugs within 3 months before screening or gene therapy/stem cell transplant within 2 years
  • Positive pregnancy test for women of childbearing potential
  • Current treatment with miglustat at recommended dose for most of past 12 months and considered satisfactorily treated, without a 1-month washout period before study medication

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 34 locations

1

UCSF Children's Hospital and Research Center at Oakland

Oakland, California, United States, 94609

Actively Recruiting

2

University of Minnesota Medical School

Minneapolis, Minnesota, United States, 55455

Not Yet Recruiting

3

Mayo Clinic Children's Center - PIN

Rochester, Minnesota, United States, 55905

Actively Recruiting

4

Children's Medical Center Dallas

Dallas, Texas, United States, 75235

Not Yet Recruiting

5

Lysosomal Rare Disorders Research and Treatment Center

Fairfax, Virginia, United States, 22030-7404

Actively Recruiting

6

Hospital Universitario Austral

Ciudad Autónoma Buenos Aires, Buenos Aires, Argentina, B1629AHJ

Actively Recruiting

7

Hospital de Niños de La Santisima Trinidad

Córdoba, Córdoba Province, Argentina, X5004 ASL

Actively Recruiting

8

Women's and Children's Hospital

North Adelaide, South Australia, Australia, 5006

Actively Recruiting

9

Royal Melbourne Hospital

Parkville, Victoria, Australia, 3050

Not Yet Recruiting

10

Royal Children's Hospital Melbourne - PIN

Parkville, Victoria, Australia, 3052

Not Yet Recruiting

11

Instituto Fernandes Figueira

Rio de Janeiro, Rio de Janeiro, Brazil, 22250-020

Not Yet Recruiting

12

Hospital de Clinicas de Porto Alegre (HCPA) - PPDS

Porto Alegre, Rio Grande do Sul, Brazil, 90560-030

Actively Recruiting

13

Hospital Pequeno Principe

Curitiba, Brazil

Not Yet Recruiting

14

M.A.G.I.C. Clinic Ltd. Metabolics and Genetics in Calgary

Calgary, Alberta, Canada, T3B 6A8

Not Yet Recruiting

15

University of Alberta Medical Genetics Clinic

Edmonton, Alberta, Canada, T6G 2B7

Not Yet Recruiting

16

Centre Hospitalier de l'Universite de Montreal-1000 rue Saint-Denis

Montreal, Quebec, Canada, H2X 0C1

Not Yet Recruiting

17

SphinCS GmbH

Höchheim, Germany, 65239

Not Yet Recruiting

18

Amrita Institute of Medical Sciences and Research Centre

Ernākulam, Kerala, India, 682041

Actively Recruiting

19

All India Institute of Medical Sciences (AIIMS) - New Delhi

New Delhi, National Capital Territory of Delhi, India, 110029

Actively Recruiting

20

JK Lone Hospital

Jaipur, Rajasthan, India, 302004

Actively Recruiting

21

Christian Medical College and Hospital

Vellore, Tamil Nadu, India, 632004

Not Yet Recruiting

22

Fondazione IRCCS Istituto Neurologico Carlo Besta

Milan, Italy, 20133

Actively Recruiting

23

Hospital Universitario Dr. Jose Eleuterio González

Monterrey, Nuevo León, Mexico, 64460

Not Yet Recruiting

24

Centenario Hospital Miguel Hidalgo

Aguascalientes, Mexico, 20000

Not Yet Recruiting

25

ULS de Santo António, EPE - Centro Materno Infantil Norte

Porto, Porto District, Portugal, 4050-651

Actively Recruiting

26

Hospital Universitario Vall d'Hebron - PPDS

Barcelona, Barcelona, Spain, 8035

Actively Recruiting

27

Hospital Infantil Universitario Niño Jesus - PIN

Madrid, Madrid, Spain, 28009

Actively Recruiting

28

Inselspital - Universitätsspital Bern

Bern, Canton of Bern, Switzerland, 3010

Actively Recruiting

29

Balcali Hastanesi Saglik Uygulama ve Arastirma Merkezi

Adana, Adana, Turkey (Türkiye), 1250

Not Yet Recruiting

30

Gazi Universitesi Saglik Arastirma ve Uygulama Merkezi

Çankaya, Ankara, Turkey (Türkiye), 6500

Actively Recruiting

31

Ege Universitesi Tip Fakultesi

Bornova, İzmir, Turkey (Türkiye), 35100

Not Yet Recruiting

32

Great Ormond Street Hospital

London, London, United Kingdom, WC1N 3JH

Not Yet Recruiting

33

University College London Hospitals (UCLH)

London, Middlesex, United Kingdom, WC1N 3BG

Not Yet Recruiting

34

Royal Manchester Children's Hospital

Manchester, United Kingdom, M13 9WL

Not Yet Recruiting

Loading map...

Research Team

P

Patient Advocacy Representative

CONTACT

C

Contact for Healthcare Professionals

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here